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Background: The increasing morbidity and mortality rates associated with Acinetobacter 
baumannii are due to the emergence of drug resistance and the limited treatment options. 
We compared characteristics of colistin-resistant Acinetobacter baumannii (CR-AB) clini-
cal isolates recovered from patients with and without prior colistin treatment. We assessed 
whether prior colistin treatment affects the resistance mechanism of CR-AB isolates, mor-
tality rates, and clinical characteristics. Additionally, a proper method for identifying CR-
AB was determined.
Methods: We collected 36 non-duplicate CR-AB clinical isolates resistant to colistin. Anti-
microbial susceptibility testing, Sanger sequencing analysis, molecular typing, lipid A 
structure analysis, and in vitro synergy testing were performed. Eleven colistin-susceptible 
AB isolates were used as controls.
Results: Despite no differences in clinical characteristics between patients with and with-
out prior colistin treatment, resistance-causing genetic mutations were more frequent in 
isolates from colistin-treated patients. Distinct mutations were overlooked via the Sanger 
sequencing method, perhaps because of a masking effect by the colistin-susceptible AB 
subpopulation of CR-AB isolates lacking genetic mutations. However, modified lipid A 
analysis revealed colistin resistance peaks, despite the population heterogeneity, and peak 
levels were significantly different between the groups. 
Conclusions: Although prior colistin use did not induce clinical or susceptibility differ-
ences, we demonstrated that identification of CR-AB by sequencing is insufficient. We 
propose that population heterogeneity has a masking effect, especially in colistin non-
treated patients; therefore, accurate testing methods reflecting physiological alterations of 
the bacteria, such as phosphoethanolamine-modified lipid A identification by matrix-as-
sisted laser desorption ionization-time of flight, should be employed.
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INTRODUCTION
Acinetobacter baumannii (AB) has become associated with in-
creasing morbidity and mortality rates in hospitals in the last two 
decades, owing to the emergence of drug resistance and limited 
treatment options [1-4]. Recently, an increase in carbapenem 
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resistance among AB strains has been reported [5, 6]. These 
carbapenem-resistant AB strains also frequently display resis-
tance to other antibiotics, consequently posing an eminent clini-
cal threat. Thus, interest in “old” antibiotics has been rekindled 
[7, 8].
Colistin, introduced in the 1950s to treat infections caused by 
gram-negative bacteria (GNB), exerts bactericidal activity by 
displacing the membrane-stabilizing calcium and magnesium 
ions and targets the polyanionic lipopolysaccharide (LPS) com-
ponents [9, 10]. However, because it induced nephrotoxicity 
and neurotoxicity, it was replaced by safer antimicrobial agents 
(e.g., aminoglycosides) [11, 12]. Despite these potential side ef-
fects, worldwide dissemination of extensively drug-resistant 
GNB (XDR-GNB) has rekindled the usage of this drug in clinical 
settings as a last-resort treatment.
The clinical use of colistin for XDR-GNB infections has led to 
the development of colistin resistance (CR) in GNB species [13-
15], and reports on the occurrence of colistin-resistant AB (CR-
AB) are increasing globally [2]. Previous in vivo studies have 
demonstrated that CR  in AB is mediated by a complete loss of 
LPS production through mutations in LPS-producing genes 
(lpxA, lpxC, lpxD, and lpsB) [16, 17] or by modification of lipid 
A components of LPS through mutations in pmrA and pmrB 
genes. These genes regulate the expression of the downstream 
target pmrC, which encodes an inner membrane phosphoetha-
nolamine (PE) transferase modifying the outer membrane lipid 
A [18, 19]. Recently, the emergence of a plasmid-mediated 
mobile CR gene, mcr-1, in Enterobacteriaceae has been re-
ported [20].
Most CR-AB clinical strains are reported to acquire resistance 
by in vivo selection during colistin treatment [21]; however, 
clonal spreading of CR-AB strains causing infections or coloni-
zation in patients without colistin treatment history has also 
been reported recently [1]. Both in vitro and in vivo models 
have shown that mutations in the PmrAB system lead to de-
creased fitness and virulence compared with that of colistin-
susceptible (CS) parental strains [22-24]. However, these stud-
ies evaluated serially obtained CR isolates and their parental CS 
strains only and thus did not consider the characteristics of dif-
ferent clinical CR-AB isolates obtained from different patients 
with and without history of colistin administration [23-26]. 
We compared CR-AB isolates recovered from patients with 
and without prior colistin treatment to assess whether prior co-
listin treatment affects CR in CR-AB isolates, patient demo-
graphics, mortality rates, or genetic mutations. Additionally, 
mortality rate was assessed to determine clinical characteristics. 
METHODS
1. Bacterial isolates
In total, 36 non-duplicate AB clinical isolates resistant to both 
carbapenems and colistin were collected from a tertiary care 
hospital in Seoul, Korea, from April 2012 to December 2014. At 
the time of sample collection, 18 patients had received previous 
colistin treatment (Group CT), and the rest had not (Group non-
CT). For comparison, AB isolates (N=11) that were resistant to 
carbapenems but susceptible to colistin were also studied. Bac-
terial species were identified by partial rpoB gene sequences 
and PCR detection of blaOXA-51-like. Patient data, including acute 
physiology and chronic health evaluation (APACHE II) score, 
use of colistin treatment, and 30-day mortality from the day of 
AB recovery, were examined retrospectively using electronic 
medical records. Multivariate logistic regression analysis was 
performed to identify risk factors associated with 30-day mortal-
ity from the day of CR-AB recovery. This project was approved 
by the Institutional Review Board of Yonsei University Severance 
Hospital, Seoul, Korea (4-2017-0758).
2. Antimicrobial susceptibility testing
The susceptibility of the isolates to colistin, meropenem, imipe-
nem, piperacillin-tazobactam, ceftazidime, cefepime, gentami-
cin, tobramycin, amikacin, tetracycline, ciprofloxacin, and trim-
ethoprim/sulfamethoxazole was determined by the disk diffusion 
method following the CLSI guidelines [27]. Minimum inhibitory 
concentrations (MICs) of meropenem and imipenem were de-
termined by using Etest (bioMérieux, Inc., Durham, NC, USA). 
Colistin MIC was determined by the broth microdilution method, 
following recommendations of the Joint CLSI-EUCAST Poly-
myxin Breakpoints Working Group [28]. Synergistic effects of 
drug combinations of colistin (32–4,096 μg/mL) either with me-
ropenem (4–256 μg/mL) or with rifampicin (0.25–32 μg/mL) 
were evaluated by the checkerboard method [29] in microtiter 
plates. The fractional inhibitory concentration (FIC) index of 
each drug combination was determined by dividing the MIC of 
each drug when used in combination by the MIC of each drug 
when used alone. The effect of a drug combination was deter-
mined by the FIC index: ≤0.5, a synergistic effect; 0.5–4.0, 
neutrality; and >4.0 an antagonistic effect.
3. PCR analysis of drug-resistant genes
A series of PCR experiments (primer information available upon 
request) were conducted to detect the OXA carbapenemase 
genes blaOXA-23-like, blaOXA-24-like, blaOXA-48-like, and blaOXA-58-like [30]; 
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the metallo-β-lactamase genes blaIMP, blaVIM, and blaNDM; and the 
serine carbapenemase genes blaGES and blaKPC [31]. The pres-
ence of ISAba1 upstream from the blaOXA-51-like gene was detected 
by PCR [32]. 
4.  Genomic analysis of genes associated with colistin 
resistance
Genes associated with CR in AB (pmrA, pmrB, pmrC, lpxA, 
lpxC, lpxD, and lpsB) were analyzed by Sanger sequencing [17, 
33]. The AB ATCC 17978 strain and 10 randomly selected co-
listin-susceptible AB (CS-AB) isolates were used as controls to 
distinguish CR-inducing mutations from polymorphisms. The 
mcr-1 gene was also identified by PCR [20].
5. Analysis of lipid A structure
Lipopolysaccharides and lipid A components were extracted 
from whole bacterial cells using Tri-reagent and mild acid hy-
drolysis, and were subjected to negative-ion matrix-assisted la-
ser desorption ionization-time of flight (MALDI-TOF) mass spec-
trometry (Bruker Daltonik GmbH, Leipzig, Germany) in negative 
reflection mode. For comparison, three randomly selected CS-
AB isolates were used as controls.
6. Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE) was conducted with SmaI-
digested genomic DNA extracted from the AB clinical isolates 
using a CHEF-DRII device (Bio-Rad, Hercules, CA, USA). PFGE 
band patterns were analyzed with Molecular Analyst Fingerprint-
ing Software Ver. 3.2 (Bio-Rad). Genetic relatedness of PFGE 
profiles was interpreted using the criteria of Tenover et al [34].
7. Multilocus sequence typing (MLST)
MLST experiments were performed following the Bartual 
scheme [13]. Sequences of seven housekeeping genes (cpn60, 
gdhB, gltA, gpi, gyrB, recA, and rpoD) were used to determine 
the sequence types (STs) of the AB clinical isolates. Each ST 
number was assigned by comparing the allele sequences with 
those in MLST databases (http://pubmlst.org/abaumannii). 
Clonal complex (CC) was defined as a group of STs that shared 
five or more of seven alleles and was determined by eBURSTv.3 
(http://eburst.mlst.net).
8. Statistical analysis
All variables were evaluated for Gaussian distribution using the 
Shapiro-Wilk test. Differences were tested with the Fisher exact 
test for categorical data and with the Mann-Whitney U test for 
continuous data. Univariate and multivariate analyses were car-
ried out using logistic regression to investigate the association 
between CR, mortality rate, and potential covariates. The pres-
ence of variance inflation factors was examined for all parame-
Table 1. Baseline characteristics of study patients 
Variables
All patients 
(N=36)
CT Non-CT
P
Univariate analysis
(N=18) (N=18) OR (95% CI) P
Age (yr) 53.9±27.4 66.5 (16.0–72.0) 67.5 (44.0–71.0) 0.624 1.01 (0.98–1.03) 0.626
Male sex* 21 (58.3%) 12 (66.7%) 9 (50.0%) 0.499 2 (0.53–8.03) 0.313
Infection type* 0.472
   Bloodstream infection 7 (19.4%) 4 (22.2%) 3 (16.7%) 0.7 (0.12–3.73) 0.674
   Respiratory infection 25 (69.4%) 11 (61.1%) 14 (77.8%) 2.23 (0.53–10.41) 0.283
   Other 4 (11.1%) 3 (16.7%) 1 (5.6%)
Ventilator care* 28 (77.8%) 15 (83.3%) 13 (72.2%) 0.688 1.92 (0.39–10.89) 0.427
History of colistin treatment 18 (50.0%) 18 (100%) 0 (0%)
   Treatment duration (day) 18.9±13.1 18.0 (7.0–29.0) 0.0 (0.0–0.0)
30-day mortality 13 (36.1%) 7 (38.9%) 6 (33.3%) 0.999 1.27 (0.32–5.12) 0.729
APACHE II 12.6±4.2 13.2±4.2 11.9±4.3 0.92 (0.78–1.08) 0.339
ICU stay during isolate recovery 29 (80.6%) 14 (38.9%) 15 (41.7%)
ICU admission history* 35 (97.2%) 17 (94.4%) 18 (100.0%) 0.999
Data are presented as number (%), mean±SD for parametric variables or median [1st quartile–3rd quartile] for non-parametric variables.
*Categorical variables included in logistic regression.
Abbreviations: CT, colistin treatment; APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit; OR, odds ratio; CI, confidence 
interval.
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ters of the multiple regression model. P <0.05 was considered 
statistically significant. All analyses were performed using R 
(Version 0.99.893, R Studio, Inc., Boston, MA, USA).
RESULTS
1. Clinical characteristics of patients
The characteristics of patients infected or colonized by CR-AB 
are presented in Table 1. To determine whether prior colistin 
treatment had any relevant effect on patient outcome, Groups 
CT and non-CT were compared. 
To determine the characteristics associated with higher sur-
vival rates, the “within 30-days deceased group” (13/36) was 
compared with the “alive group” (23/36) (Table 2). Only blood-
stream infection and APACHE II scores significantly differed be-
tween groups. 
2. Strain typing
MLST showed that all CR-AB isolates belonged to CC92. Among 
these, 91.7% (33/36) were identified as ST191 (Fig. 1). All iso-
lates from Group non-CT belonged to ST191, whereas the three 
non-ST191 isolates were retrieved from Group CT. The 36 CR-
AB isolates were assigned to 13 PFGE types (pulsotypes A to N) 
on the basis of banding patterns. With the exception of pulso-
type A1, isolates of pulsotypes A, F, and H did not show any CR-
related genetic mutations, and the majority (16/18) of the host 
patients belonged to Group non-CT. However, isolates of pulso-
types B, C, E, and G showed genetic mutations, and most (8/10) 
of the host patients belonged to Group CT. 
3. PCR analysis and antimicrobial susceptibility
Only the blaOXA-23-like carbapenemase gene was found in all CR-
AB isolates. No other carbapenemase genes were detected by 
PCR. ISAba1, located upstream from the blaOXA-51-like gene, was 
not detected. All CR-AB isolates were resistant to more than 
three antimicrobial classes by a disk diffusion susceptibility test 
(data not shown). All colistin MICs determined by the broth mi-
crodilution method were >128 μg/mL. 
4. Mutations in genes associated with colistin resistance
All isolates with genetic mutations had mutated pmrB gene, and 
pmrB gene was the most frequently mutated (16/36, 44.4%). 
Table 2. Univariate and multivariate analyses of risk factors for 30-day mortality
Variables
Death
(N=13)
Survival
(N=23)
P
Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Age (yr) 66.0 (4.0–71.0) 67.0 (50.5–71.5) 0.419 1.02 (0.99–1.05) 0.142
Male sex* 5 (38.5%) 10 (43.5%) 0.999 1.23 (0.31–5.17) 0.770
Infection type* 0.005 
   Bloodstream infection 6 (46.2%) 1 (4.3%) 0.05 (0–0.38) 0.012 0.02 (0–0.22) 0.011
   Respiratory infection 7 (53.8%) 18 (78.3%) 3.09 (0.72–14.23) 0.134
   Other 0 (0.0%) 4 (17.4%)
Ventilator care* 13 (100.0%) 15 (65.2%) 0.046 NA 0.994
History of colistin treatment* 7 (53.8%) 11 (47.8%) 0.999 1.27 (0.32–5.12) 0.729
   Treatment duration (day) 21.7±18.5 17.2±8.9 0.562 0.97 (0.89–1.05) 0.471
APACHE II 14.6±4.3 11.4±3.7 0.025 0.81 (0.65–0.97) 0.035 0.73 (0.53–0.92) 0.019
ICU admission history* 13 (100.0%) 22 (95.7%) 0.999 NA 0.995
MLST* 0.604 NA 0.995
   ST191 13 (100.0%) 20 (87.0%)
   ST357 0 (0.0%) 1 (4.3%)
   ST858 0 (0.0%) 1 (4.3%)
   ST872 0 (0.0%) 1 (4.3%)
Data are presented as N (%), mean±SD for parametric variables, or median [1st quartile–3rd quartile] for non-parametric variables. Bold values are statisti cally 
significant (P <0.05).
*Categorical variables included in logistic regression.
All colistin-resistant Acinetobacter baumannii isolates were within clonal cluster 92.
Abbreviations: OR, odds ratio; CI, confidence interval; APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit; MLST, Multilo-
cus sequence typing.
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Genetic mutations were more frequently observed in isolates 
from Group CT than in those from Group non-CT patients 
(72.2% [13/18] and 11.1% [2/18], respectively, P ≤0.001). CR-
AB 32, 34, 35, and 36 had the same mutation in pmrB 
(g.938_939insTTT) and belonged to the same strain type ac-
cording to both PFGE (pulsotype G) and MLST (ST191). These 
patients stayed in the same isolated location (ICU-H) for more 
than 47 days. Based on the available microbiological and clini-
cal information, we concluded that these isolates were of the 
same strain, and clonal spread was revealed. Interestingly, with 
the exception of two isolates (CR-AB35 and 37), no genetic mu-
tations were detected in isolates from Group non-CT. 
5. Lipid A structure
Lipid A MALDI-TOF mass spectra of CR-AB isolates showed 
distinct profiles (Fig. 2). Common intensity peaks at m/z 1729, 
1912, and 2139 were found in both CS-AB and CR-AB, indicat-
ing normal hexa-, hepta-, and octa-acylated lipid A, whereas in 
some isolates, the hexa- and octa-acylated lipid A peaks were 
completely changed to phosphoethanolaminated lipid A (hexa-
acylated: 1/36, octa-acylated: 9/36). In each isolate, intensities 
of other lipid A components were compared with that of the 
hepta-acylated lipid A peak (Table 3), which was set as 100% 
because some hexa- and octa-acylated peaks were completely 
lost, and therefore were not suitable as reference peaks. 
Peak intensity was significantly higher at two phosphoethanol-
amine (PE)-modified hexa-, hepta- and octa-acylated lipid A 
(P =0.008, <0.001, and 0.002, respectively) in isolates from 
Group CT than in those from Group non-CT. Furthermore, origi-
nal hexa-acylated lipid A intensity peaks were significantly lower 
(P =0.021), and two PE-modified octa-acylated lipid A with 4C-
H2O was significantly higher in isolates from Group CT (P =0.01). 
The lipid A composition determined by MALDI-TOF M/S divided 
the CR-AB strains into strains harboring pmrB mutation and those 
having normal pmrB (Table 4). When lipid A peaks were grouped 
and analyzed according to the number of substitutions occurring 
Fig. 1. Dendrogram showing cluster analysis of SmaI-digested pulsed-field gel electrophoresis patterns from colistin-resistant Acinetobacter 
baumannii isolates. Mutations from genomic analysis of genes associated with colistin resistance are listed on the right in bold font. Note 
that CR-AB32, 34, 35, and 36 had the same mutation in the pmrB gene (insertion TTT at g.938_939) and were isolated from a single loca-
tion (ICU-H) within 47 days (highlighted by a black rectangle). 
Abbreviations: ABA, Acinetobacter baumannii; CC, clonal complex; CCU, coronary care unit; GW, general ward; ICU, intensive care unit; PFGE, pulsed-field 
gel electrophoresis; ST, sequence type; CS-AB, colistin-susceptible Acinetobacter baumannii; CR-AB, colistin-resistant Acinetobacter baumannii. 
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Fig. 2. Mass spectrometry of lipid A extracted from colistin-susceptible isolates and CR-AB. (A) ATCC 17978, wild type CS-AB. (B) CR-
AB18, Group non-CT. (C) CR-AB14, Group CT. The mass (m/z) of peaks only detected in CR-AB strains is indicated in bold. 
Abbreviations: Hexa, hexa-acylated lipid A; Hepta, hepta-acylated lipid A; Octa, octa-acylated lipid A; PE, phosphoethanolamine; C, carbon; CS-AB, colistin-
susceptible Acinetobacter baumannii; CR-AB, colistin-resistant Acinetobacter baumannii.
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in pmrB, pmrC, and lpsB genes, only the octa-acylated lipid A 
peak and its PE-modified forms were statistically different. 
6. In vitro synergy testing
In vitro synergistic resistance effects (ΣFIC ≤0.5) for CR-AB iso-
Table 3. Genetic characteristics and lipid A composition of colistin-resistant Acinetobacter baumannii isolates from patients with and with-
out colistin treatment
Colistin-susceptible  
A. baumannii (N=3)†
Colistin-resistant A. baumannii (N=36)
P
CT (N=18) Non-CT (N=18)
Relative percentage of each lipid A component peak (%)*
   Hexa 39.8 (29.8–40.6) 13.3 (2.1–49.7) 24.7 (0–58.1) 0.021
   Hexa+1-PE 0 (0–1.0) 21.2 (8.3–146.9) 24.3 (2.1–78.5) 0.448
   Hexa+2-PE 0 (0–0) 2.1 (0–43.3) 0 (0–3.7) 0.008
   Hepta 100 (100–100) 100 (100–100) 100 (100–100) -
   Hepta+1-PE 0 (0–1.0) 143.5 (63.5–353.4) 108.6 (62.2–204.7) 0.018
   Hepta+2-PE 0 (0–0) 29.4 (0–71.1) 1.9 (0–31.6) <0.001
   Octa 9.1 (2.2–12.9) 5.5 (0–11.6) 6.6 (0–12.6) 0.355
   Octa+1-PE 0 (0–0) 47.3 (15.2–137.7) 58.9 (25.7–316.7) 0.393
   Octa+2-PE 0 (0–0) 51.3 (0.3–220.8) 5.8 (1.7–255.7) 0.002
   Octa+2-PE+4C-H2O 0 (0–0) 16.3 (0–100.7) 0 (0–58.2) 0.001
Isolates with genetic mutations, N (%)
   Overall 0 (0%) 13 (72.2%) 2 (11.1%) <0.001
   pmrB 13 (72.2%) 2 (11.1%) <0.001
   pmrC 4 (22.2%) 2 (11.1%) 0.658
   lpsB 1 (5.6%) 0 (0%) 1.000
Bold values are statistically significant (P <0.05).
*Data represent the relative intensity (%) and their range compared with hepta-acylated lipid A, set as 100%.
†For comparison, three randomly selected colistin-susceptible Acinetobacter baumannii clinical isolates were used as controls.
Abbreviations: CT, colistin treatment; Hexa, hexa-acylated lipid A; Hepta, hepta-acylated lipid A; Octa, octa-acylated lipid A; PE, phosphoethanolamine; C, 
carbon.
Table 4. Lipid A composition with genetic pmrB and other gene mutations of colistin-resistant Acinetobacter baumannii 
Relative percentage of 
each lipid A component 
peak (%)*
Genetic mutation not 
detected 
(N=21)
Genetic mutation 
detected 
(N=15)
P
pmrB gene single 
mutation 
(N=7)
pmrB gene two 
mutations 
(N=2)
pmrB gene and other 
mutation 
(N=6)
P
Hexa 24.8 (18.9–37.4) 11.3 (8.7–14.7) <0.001 15.8 (10.8–19.2) 11.9 (10.3–13.5) 8.7 (2.0–11.3) 0.099
Hexa+1-PE 25.2 (20.0–32.8) 19.2 (17.0–22.4) 0.026 19.2 (17.4–22.0) 14.7 (10.6–18.9) 20.8 (16.7–23.5) 0.588
Hexa+2-PE 0.0 (0.0–1.1) 3.6 (1.1–5.6) 0.002 5.0 (3.0–6.4) 4.1 (0.7–7.4) 0.7 (0.0–3.6) 0.074
Hepta  21 (100.0%) 15 (100.0%) - 7 (100.0%) 2 (100.0%) 6 (100.0%) 0.247
Hepta+1-PE 107.1 (84.6–127.7) 175.9 (138.1–196.4) <0.001 175.9 (140.8–179.9) 131.6 (118.5–144.7) 196.4 (136.8–219.5) 0.381
Hepta+2-PE 1.8 (0.6–4.1) 31.6 (25.2–36.9) <0.001 31.4 (29.4–34.8) 27.1 (22.0–32.2) 33.9 (11.4–42.6) 0.944
Octa 5.6 (0.0–10.0) 6.0 (3.2–7.5) 0.686 6.0 (5.1–6.7) 3.4 (1.6–5.1) 7.5 (0.0–8.2) 0.479
Octa+1-PE 71.3 (44.6–85.4) 42.8 (31.8–70.1) 0.127 51.5±29.4 19.9±4.5 65.0±27.4 0.458
Octa+2-PE 5.8 (3.0–13.9) 85.3 (44.0–129.3) <0.001 55.3 (44.0–105.3) 34.7 (31.0–38.4) 125.8 (90.1–181.2) 0.029
Octa+2-PE+4C-H2O 0.0 (0.0–0.0) 23.9 (15.8–52.6) <0.001 21.1 (4.4–46.4) 15.8 (15.3–16.2) 45.5 (32.1–58.2) 0.201
Data are presented as number (%), mean±SD for parametric variables or median [1st quartile–3rd quartile] for non-parametric variables. Bold values are 
statistically significant (P <0.05)
*Data represent the relative intensity (%) and their range compared with hepta-acylated lipid A, set as 100%.
Abbreviations: Hexa, hexa-acylated lipid A; Hepta, hepta-acylated lipid A; Octa, octa-acylated lipid A; PE, phosphoethanolamine; C, carbon.
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lates were most frequently observed for the colistin-meropenem 
combination (94.4%, 34/36) followed by the colistin-rifampicin 
combination (83.3%, 30/36). Although the synergy testing did 
not show significant differences (colistin-meropenem, P =0.467; 
colistin-rifampicin, P =0.655), combinations of colistin with me-
ropenem or rifampin lowered the colistin MICs by 16-fold 
(range, 4–128-fold) and 8-fold (range, 4–128-fold), respectively 
(data not shown). 
DISCUSSION
In our comparison of the characteristics of CR-AB clinical iso-
lates recovered from CT and non-CT patients, no specific pa-
tient trait was found relevant to the clinical outcome. As for the 
mortality rate, the APACHE II score and bloodstream infections 
were two noteworthy markers that should be taken into consid-
eration when managing CR-AB-infected patients. These find-
ings were expected because the APACHE II scoring system is 
designed to measure disease severity in patients admitted to 
ICUs, and because bloodstream infections have a negative im-
pact on patient outcome [35]. Although there were no signifi-
cant differences in terms of patient characteristics, the causative 
CR-AB isolates presented obvious differences associated with 
CR, such as altered lipid A components, as indicated by MALDI-
TOF M/S and genetic mutations associated with outer mem-
brane modification.
Most of the CR-AB isolates from Group non-CT did not show 
any genetic mutations, whereas the revised lipid A component 
was characterized by shifted lipid A component peaks in 
MALDI-TOF M/S. Two potential hypotheses explain these unex-
pected results. First, the isolates may be a hetero-population 
composed of subpopulations of CR-AB and CS-AB lacking any 
evident genetic mutation, thus presenting with so-called hetero-
resistance [3]. Heteroresistance may be the primary stage, 
which in the presence of colistin, results in the proliferation of 
resistant subpopulations, and may prolong the treatment period 
or even lead to mortality [3, 15, 36, 37]. The major subpopula-
tion of CS-AB possibly produces erroneous colistin susceptibility 
data when using commercially automated systems and disk dif-
fusion tests [3], whereas multiplication of the minor CR-AB sub-
population results in at least little growth in the presence of high 
concentrations of colistin by broth dilution, resulting in high 
MICs [3, 36]. The different density of subpopulations might 
mask genetic mutations in CR-AB strains analyzed by Sanger 
sequencing. Similar findings have been demonstrated in Myco-
bacterium tuberculosis [38, 39]. PCR-based detection was not 
sufficient to identify heteroresistance, because minor allele fre-
quencies of less than 15% were below the detection threshold 
of the method [40]. In addition, the CS-AB population feasibly 
flourished owing to better fitness in a colistin-free environment 
compared with the CR-AB population. As a consequence, the 
proportion switch of the two subpopulations might have pro-
duced ambiguous results. Secondly, although less likely, a novel 
mechanism conferring resistance to colistin might be involved. 
Since this study focused on genetic mutations in known CR-as-
sociated genes, unknown mechanisms of resistance might have 
been missed. Future studies should conduct a complex func-
tional whole-genome analysis.
Regardless of the population heterogeneity, CR-AB was de-
tectable by MALDI-TOF M/S, based on distinct spectra of modi-
fied lipid A compositions. Modification of lipid A by the addition 
of PE to the hexa-, hepta-, and octa-acylated lipid A has been 
suggested as a major mechanism of CR in AB. Similarly, even 
though some isolates exhibited unmodified lipid A peaks in this 
study, CR-AB displayed shifted peaks of one or two PE additives 
to the three lipid A moieties. Interestingly, the relative peak lev-
els of PE-modified compared with unmodified lipid A compo-
nents were much more elevated in Group CT. Notably, the rela-
tive peak levels of the two PE modified hepta-acylated lipid A 
moieties clearly separated the two groups. 
Most of the CR-AB isolates from both groups showed a syner-
gistic effect of colistin upon addition of meropenem or rifampin: 
synergism of both combinations was observed for most isolates, 
without any noticeable difference between combinations or be-
tween groups. Thus, combination treatment with either merope-
nem or rifampin should be considered for both CT and non-CT 
patients.
Out study has some limitations. As its main scope was to de-
termine characteristics of CR-AB in clinical isolates and did not 
entail confirmation of heteroresistance, we could not confirm 
heteroresistant AB. Our data were collected from a single center 
in Korea, so the findings may not be generalized to other institu-
tions. The limited number of CR-AB isolates precludes definitive 
conclusions on heterogeneous AB populations and CR.
Our study demonstrated that although there were no differ-
ences in clinical characteristics between Groups CT and non-
CT, there were pathological differences, including those involv-
ing characteristics useful in diagnosing CR-AB. Population het-
erogeneity masked resistance-causing genetic mutations, tradi-
tionally determined by Sanger sequencing, especially in Group 
non-CT; therefore, to identify CR, accurate testing methods re-
flecting physiological alteration of the bacteria, such as PE-mod-
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ified lipid A identification by MALDI-TOF M/S, should be carried 
out. Since colistin heteroresistance is common in patients with-
out prior drug treatment and can be caused by better bacterial 
fitness in the colistin-free environment, lipid A analysis shows 
clearer results for CR-AB isolates. Broth microdilution was found 
to accurately determine CR in AB regardless of population het-
erogeneity, which prevented exact susceptibility interpretation 
because of the subpopulations of CR-AB. Furthermore, combi-
nation treatment, specifically with meropenem and rifampicin, 
should be considered for the treatment of CR-AB infections.
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